These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20303626)

  • 1. Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors.
    Choi SJ; Cho JH; Im I; Lee SD; Jang JY; Oh YM; Jung YK; Jeon ES; Kim YC
    Eur J Med Chem; 2010 Jun; 45(6):2578-90. PubMed ID: 20303626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors.
    Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R
    Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.
    Probst GD; Bowers S; Sealy JM; Stupi B; Dressen D; Jagodzinska BM; Aquino J; Gailunas A; Truong AP; Tso L; Xu YZ; Hom RK; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Sham HL; Jagodzinski J; Toth G; Brecht E; Yao N; Pan H; Lin M; Artis DR; Ruslim L; Bova MP; Sinha S; Yednock TA; Gauby S; Zmolek W; Quinn KP; Sauer JM
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6034-9. PubMed ID: 20822903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of Alzheimer's BACE-1 with 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridine structure.
    Miri R; Firuzi O; Razzaghi-Asl N; Javidnia K; Edraki N
    Arch Pharm Res; 2015 Apr; 38(4):456-69. PubMed ID: 24771353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors.
    Iserloh U; Wu Y; Cumming JN; Pan J; Wang LY; Stamford AW; Kennedy ME; Kuvelkar R; Chen X; Parker EM; Strickland C; Voigt J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):414-7. PubMed ID: 18023580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors.
    Huang W; Yu H; Sheng R; Li J; Hu Y
    Bioorg Med Chem; 2008 Dec; 16(24):10190-7. PubMed ID: 19013073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of potent and selective BACE-1 inhibitors.
    Björklund C; Oscarson S; Benkestock K; Borkakoti N; Jansson K; Lindberg J; Vrang L; Hallberg A; Rosenquist A; Samuelsson B
    J Med Chem; 2010 Feb; 53(4):1458-64. PubMed ID: 20128595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic.
    Wångsell F; Russo F; Sävmarker J; Rosenquist A; Samuelsson B; Larhed M
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4711-4. PubMed ID: 19576765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
    Wang YS; Strickland C; Voigt JH; Kennedy ME; Beyer BM; Senior MM; Smith EM; Nechuta TL; Madison VS; Czarniecki M; McKittrick BA; Stamford AW; Parker EM; Hunter JC; Greenlee WJ; Wyss DF
    J Med Chem; 2010 Feb; 53(3):942-50. PubMed ID: 20043700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents.
    Sealy JM; Truong AP; Tso L; Probst GD; Aquino J; Hom RK; Jagodzinska BM; Dressen D; Wone DW; Brogley L; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Dappen MS; Toth G; Pan H; Ruslim L; Miller J; Bova MP; Sinha S; Quinn KP; Sauer JM
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6386-91. PubMed ID: 19811916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyramine fragment binding to BACE-1.
    Kuglstatter A; Stahl M; Peters JU; Huber W; Stihle M; Schlatter D; Benz J; Ruf A; Roth D; Enderle T; Hennig M
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1304-7. PubMed ID: 18226904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease.
    Huang W; Lv D; Yu H; Sheng R; Kim SC; Wu P; Luo K; Li J; Hu Y
    Bioorg Med Chem; 2010 Aug; 18(15):5610-5. PubMed ID: 20620068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead.
    Baxter EW; Conway KA; Kennis L; Bischoff F; Mercken MH; Winter HL; Reynolds CH; Tounge BA; Luo C; Scott MK; Huang Y; Braeken M; Pieters SM; Berthelot DJ; Masure S; Bruinzeel WD; Jordan AD; Parker MH; Boyd RE; Qu J; Alexander RS; Brenneman DE; Reitz AB
    J Med Chem; 2007 Sep; 50(18):4261-4. PubMed ID: 17685503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: prime side chromane-containing inhibitors.
    Ng RA; Sun M; Bowers S; Hom RK; Probst GD; John V; Fang LY; Maillard M; Gailunas A; Brogley L; Neitz RJ; Tung JS; Pleiss MA; Konradi AW; Sham HL; Dappen MS; Adler M; Yao N; Zmolek W; Nakamura D; Quinn KP; Sauer JM; Bova MP; Ruslim L; Artis DR; Yednock TA
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4674-9. PubMed ID: 23856050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.
    Iserloh U; Pan J; Stamford AW; Kennedy ME; Zhang Q; Zhang L; Parker EM; McHugh NA; Favreau L; Strickland C; Voigt J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):418-22. PubMed ID: 17980584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads.
    Huang Y; Strobel ED; Ho CY; Reynolds CH; Conway KA; Piesvaux JA; Brenneman DE; Yohrling GJ; Moore Arnold H; Rosenthal D; Alexander RS; Tounge BA; Mercken M; Vandermeeren M; Parker MH; Reitz AB; Baxter EW
    Bioorg Med Chem Lett; 2010 May; 20(10):3158-60. PubMed ID: 20399652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of potent hydroxyethylamine (HEA) BACE-1 inhibitors carrying prime side 4,5,6,7-tetrahydrobenzazole and 4,5,6,7-tetrahydropyridinoazole templates.
    Sund C; Belda O; Borkakoti N; Lindberg J; Derbyshire D; Vrang L; Hamelink E; Åhgren C; Woestenenk E; Wikström K; Eneroth A; Lindström E; Kalayanov G
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6721-7. PubMed ID: 23010268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and development of BACE-1 inhibitors.
    Cumming JN; Iserloh U; Kennedy ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):536-56. PubMed ID: 15338962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
    Geschwindner S; Olsson LL; Albert JS; Deinum J; Edwards PD; de Beer T; Folmer RH
    J Med Chem; 2007 Nov; 50(24):5903-11. PubMed ID: 17985861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.